menu
    • menu

    Find Dexmethylphenidate manufacturers, exporters & distributors on PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    12

    API Suppliers

    API Suppliers

    8

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    9

    NDC API

    NDC API

    0

    VMF

    NDC API

    7

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 6,421

    MARKET PLACE

    2

    API

    0

    FDF

    2INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    120

    FDF Dossiers

    FDF Dossiers

    112

    FDA Orange Book

    FDA (Orange Book)

    8

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    30DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    18

    US Patents

    3

    US Exclusivities

    6

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    41

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    2,876,740

    Annual Reports

    2,161

    Finished Drug Prices

    Listed Dossiers

    256 RELATED EXCIPIENT COMPANIES

    434EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Dexmethylphenidate hcl, Focalin, D-threo-methylphenidate hydrochloride, 19262-68-1, Focalin xr, 23655-65-4
    Molecular Formula
    C14H20ClNO2
    Molecular Weight
    269.77  g/mol
    InChI Key
    JUMYIBMBTDDLNG-OJERSXHUSA-N
    FDA UNII
    1678OK0E08
    Dexmethylphenidate
    A methylphenidate derivative, DOPAMINE UPTAKE INHIBITOR and CENTRAL NERVOUS SYSTEM STIMULANT that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
    1 2D Structure

    Dexmethylphenidate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
    2.1.2 InChI
    InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
    2.1.3 InChI Key
    JUMYIBMBTDDLNG-OJERSXHUSA-N
    2.1.4 Canonical SMILES
    COC(=O)C(C1CCCCN1)C2=CC=CC=C2.Cl
    2.1.5 Isomeric SMILES
    COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    1678OK0E08
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Dexmethylphenidate

    2. Focalin

    3. Focalin Xr

    4. Hydrochloride, Dexmethylphenidate

    5. Xr, Focalin

    2.3.2 Depositor-Supplied Synonyms

    1. Dexmethylphenidate Hcl

    2. Focalin

    3. D-threo-methylphenidate Hydrochloride

    4. 19262-68-1

    5. Focalin Xr

    6. 23655-65-4

    7. Metadate Cd

    8. Metadate Er

    9. Equasym Xl

    10. Dexmethylphenidate Hydrochloride [usan]

    11. Ritalin

    12. 4b3sc438hi

    13. Dex-methylphenidate Hydrochloride

    14. Methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;hydrochloride

    15. 1678ok0e08

    16. Methylphenidate D-threo-form Hydrochloride

    17. Methyl (2r)-phenyl((2r)-piperidin-2-yl)acetate Hydrochloride

    18. 19262-68-1 (hcl)

    19. Methyl (2r)-2-phenyl-2-[(2r)-piperidin-1-ium-2-yl]acetate;chloride

    20. Quillichew

    21. Quillivant

    22. Aptensio

    23. Foquest

    24. Oros Mph

    25. Aptensio Xr

    26. Methylin Er

    27. Ritalin La

    28. Ritalin Sr

    29. Chembl904

    30. (r)-methyl 2-phenyl-2-((r)-piperidin-2-yl)acetate Hydrochloride

    31. Daytrana

    32. Dexmethylphenidate Hydrochloride (usan)

    33. Spd544

    34. Spd-544

    35. Dl-threo-methylphenidate Hcl

    36. Biphentin

    37. Equasym

    38. Methypatch

    39. Metadate Mr

    40. Unii-1678ok0e08

    41. Equasym Ir

    42. Ritalin Qd

    43. Focalin (tn)

    44. Dl-threo-methylphenidate Hydrochloride

    45. Adhansia Xr

    46. Jornay Pm

    47. Methyl .alpha.-phenyl-2-piperidineacetate Hydrochloride

    48. Unii-4b3sc438hi

    49. Nwp-06

    50. Dtxsid50940927

    51. D-threo Methylphenidate Hydrochloride

    52. Akos027321667

    53. Rac-threo-methylphenidate Hydrochloride

    54. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (alphar,2r)-

    55. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (r*,r*)- (+-)-

    56. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (r-(r*,r*))-

    57. Methylphenidate Hydrochloride [mi]

    58. (+/-)-threo-methylphenidate Hydrochloride

    59. Methylphenidate Hydrochloride [jan]

    60. Methylphenidate Hydrochloride [mart.]

    61. Methylphenidate Hydrochloride [vandf]

    62. Methylphenidate Hydrochloride [who-dd]

    63. D03721

    64. Dexmethylphenidate Hydrochloride [mart.]

    65. Dexmethylphenidate Hydrochloride [vandf]

    66. Dexmethylphenidate Hydrochloride [who-dd]

    67. Methylphenidate Hydrochloride [orange Book]

    68. Methylphenidate Hydrochloride Cii [usp-rs]

    69. Methylphenidate Hydrochloride [ep Monograph]

    70. Methylphenidate Hydrochloride [usp Monograph]

    71. Dexmethylphenidate Hydrochloride [orange Book]

    72. Methylphenidate D-threo-form Hydrochloride [mi]

    73. Q47487562

    74. Azstarys Component Dexmethylphenidate Hydrochloride

    75. Dexmethylphenidate Hydrochloride Component Of Azstarys

    76. Methyl Phenyl(piperidin-2-yl)acetate--hydrogen Chloride (1/1)

    77. Methylphenidate Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)

    78. 2-piperidineacetic Acid, .alpha.-phenyl-, Methyl Ester, Hydrochloride, (r*,r*)-(+/-)-

    79. 2-piperidineacetic Acid, .alpha.-phenyl-, Methyl Ester, Hydrochloride,(.alpha.r,2r)-

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 269.77 g/mol
    Molecular Formula C14H20ClNO2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass269.1182566 g/mol
    Monoisotopic Mass269.1182566 g/mol
    Topological Polar Surface Area38.3 Ų
    Heavy Atom Count18
    Formal Charge0
    Complexity249
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameDexmethylphenidate hydrochloride
    Drug LabelFocalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormTablet; Capsule, extended release
    Routeoral; Oral
    Strength2.5mg; 5mg; 25mg; 30mg; 10mg; 15mg; 40mg; 20mg
    Market StatusTentative Approval; Prescription
    CompanyWatson Labs; Mylan Pharms; Teva Pharms; Intellipharmaceutics; Teva Pharms Usa

    2 of 6  
    Drug NameFocalin
    PubMed HealthDexmethylphenidate (By mouth)
    Drug ClassesCNS Stimulant
    Drug LabelFocalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormTablet
    RouteOral
    Strength2.5mg; 5mg; 10mg
    Market StatusPrescription
    CompanyNovartis

    3 of 6  
    Drug NameFocalin xr
    PubMed HealthDexmethylphenidate (By mouth)
    Drug ClassesCNS Stimulant
    Drug LabelFocalin XR is an extended-release formulation of dexmethylphenidate with a bi-modal release profile. Focalin XR uses the proprietary SODAS (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Focalin XR capsule contains half the dose...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormCapsule, extended release
    RouteOral
    Strength25mg; 30mg; 15mg; 5mg; 10mg; 40mg; 20mg; 35mg
    Market StatusPrescription
    CompanyNovartis

    4 of 6  
    Drug NameDexmethylphenidate hydrochloride
    Drug LabelFocalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormTablet; Capsule, extended release
    Routeoral; Oral
    Strength2.5mg; 5mg; 25mg; 30mg; 10mg; 15mg; 40mg; 20mg
    Market StatusTentative Approval; Prescription
    CompanyWatson Labs; Mylan Pharms; Teva Pharms; Intellipharmaceutics; Teva Pharms Usa

    5 of 6  
    Drug NameFocalin
    PubMed HealthDexmethylphenidate (By mouth)
    Drug ClassesCNS Stimulant
    Drug LabelFocalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threo-enantiomers. Focalin is a central nervous system (CNS) stimulant, available in 3 tabl...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormTablet
    RouteOral
    Strength2.5mg; 5mg; 10mg
    Market StatusPrescription
    CompanyNovartis

    6 of 6  
    Drug NameFocalin xr
    PubMed HealthDexmethylphenidate (By mouth)
    Drug ClassesCNS Stimulant
    Drug LabelFocalin XR is an extended-release formulation of dexmethylphenidate with a bi-modal release profile. Focalin XR uses the proprietary SODAS (Spheroidal Oral Drug Absorption System) technology. Each bead-filled Focalin XR capsule contains half the dose...
    Active IngredientDexmethylphenidate hydrochloride
    Dosage FormCapsule, extended release
    RouteOral
    Strength25mg; 30mg; 15mg; 5mg; 10mg; 40mg; 20mg; 35mg
    Market StatusPrescription
    CompanyNovartis

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Dopamine Uptake Inhibitors

    Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)

    Central Nervous System Stimulants

    A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Granules Receives USFDA approval for complex, ADHD Drug

    Details:

    A generic version of Dexmethylphenidate HCl (Dopamine/Norepinephrine reuptake inhibitor) extended-release capsules have been approved for the treatment of attention-deficit hyperactivity disorder.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: Focalin-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 11, 2020

    Granules India

    01

    Granules India Limited

    India
    arrow
    CPhI India 2024
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Granules Receives USFDA approval for complex, ADHD Drug

    Details : A generic version of Dexmethylphenidate HCl (Dopamine/Norepinephrine reuptake inhibitor) extended-release capsules have been approved for the treatment of attention-deficit hyperactivity disorder.

    Brand Name : Focalin-Generic

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 11, 2020

    Granules India

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

    Details:

    CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit hyperactivity disorder.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 12, 2024

    blank

    02

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

    Details : CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit hyperactivity disorder.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 12, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Achieves Milestone in ADHD Drug CTx-1301 for FDA Marketing Clearance

    Details:

    CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit hyperactivity disorder.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 25, 2024

    blank

    03

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cingulate Achieves Milestone in ADHD Drug CTx-1301 for FDA Marketing Clearance

    Details : CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit hyperactivity disorder.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 25, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

    Details:

    CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD in patients aged 6 years and above.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 21, 2024

    blank

    04

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

    Details : CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD in patients aged 6 years and above.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Announces Closing of $7.5 Million Public Offering

    Details:

    The company will use proceeds for research, development, and commercialization of CTx-1301 (dexmethylphenidate), a once-daily stimulant for ADHD.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $7.5 million Upfront Cash: Undisclosed

    Deal Type: Public Offering February 06, 2024

    blank

    05

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $7.5 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Cingulate Announces Closing of $7.5 Million Public Offering

    Details : The company will use proceeds for research, development, and commercialization of CTx-1301 (dexmethylphenidate), a once-daily stimulant for ADHD.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    February 06, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Announces Pricing of $7.5 Million Public Offering

    Details:

    The company will use proceeds for research, development, and commercialization of CTx-1301 (dexmethylphenidate), a once-daily stimulant for ADHD.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $7.5 million Upfront Cash: Undisclosed

    Deal Type: Public Offering February 02, 2024

    blank

    06

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $7.5 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Cingulate Announces Pricing of $7.5 Million Public Offering

    Details : The company will use proceeds for research, development, and commercialization of CTx-1301 (dexmethylphenidate), a once-daily stimulant for ADHD.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    February 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Announces Closing of $4.0 Million Public Offering

    Details:

    The Company intends to use the proceeds for continued research and development and commercialization activities of its lead candidate CTx-1301, a novel, trimodal formulation of dexmethylphenidate to treat ADHD.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $4.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering September 13, 2023

    blank

    07

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $4.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Cingulate Announces Closing of $4.0 Million Public Offering

    Details : The Company intends to use the proceeds for continued research and development and commercialization activities of its lead candidate CTx-1301, a novel, trimodal formulation of dexmethylphenidate to treat ADHD.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 13, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Announces Pricing of $4.0 Million Public Offering

    Details:

    The proceeds will fund for continued R&D and commercialization activities of company's lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a once-daily stimulant medication for attention-deficit/hyperactivity disorder.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: H.C. Wainwright & Co.

    Deal Size: $4.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering September 11, 2023

    blank

    08

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : H.C. Wainwright & Co.

    Deal Size : $4.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Cingulate Announces Pricing of $4.0 Million Public Offering

    Details : The proceeds will fund for continued R&D and commercialization activities of company's lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a once-daily stimulant medication for attention-deficit/hyperactivi...

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

    Details:

    CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Dr. Vince Clinical Research

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 06, 2023

    blank

    09

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Dr. Vince Clinical Research

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III...

    Details : CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 06, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

    Details:

    CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.


    Lead Product(s): Dexmethylphenidate

    Therapeutic Area: Psychiatry/Psychology Brand Name: CTx-1301

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 29, 2023

    blank

    10

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Cingulate Therapeutics, LLC

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexmethylphenidate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to...

    Details : CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.

    Brand Name : CTx-1301

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 29, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 10MG

    USFDA APPLICATION NUMBER - 21278

    read-more

    DOSAGE - TABLET;ORAL - 2.5MG

    USFDA APPLICATION NUMBER - 21278

    read-more

    DOSAGE - TABLET;ORAL - 5MG

    USFDA APPLICATION NUMBER - 21278

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 10M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 10MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 15M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 15MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 20M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 20MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 25M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 25MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 30M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 30MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 35M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 35MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 40M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 40MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 5MG

    USFDA APPLICATION NUMBER - 21802

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Topical

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search